Drug Profile
Research programme: anti-AML monoclonal antibody - Astellas/MD Anderson Cancer Center
Alternative Names: h8F4Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HLA antigen modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Acute-myeloid-leukaemia in USA (Parenteral)
- 07 Dec 2016 Astellas Pharma plans to file an IND application with the US FDA for Acute myeloid leukaemia
- 03 Dec 2016 Pharmacodynamics data from preclinical studies in Acute myeloid leukaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology